Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).

Trial Details

NCT ID
NCT05856981
Phase
PHASE1
Sponsor
Sairopa B.V.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • ADU-1805
  • Pembrolizumab
Locations (sample)
  • Detroit, Michigan, United States|42.33143,-83.04575
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Charlotte, North Carolina, United States|35.22709,-80.84313
  • Durham, North Carolina, United States|35.99403,-78.89862
  • Canton, Ohio, United States|40.79895,-81.37845

Key Eligibility Criteria

  • Male or female aged ≥18 years
  • Signed and dated informed consent form
  • Measurable disease according to RECIST (Safety Expansion only)
  • ECOG Performance status of 0 or 1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →